NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis

by Ed Johnson
June 26, 2021
A A
Scientist Working in The Laboratory

Scientist Working in The Laboratory

– Positive opinion based on three global Phase 3 pivotal studies evaluating the safety and efficacy of RINVOQ (15 mg or 30 mg, once daily) used with or without topical corticosteroids in adults and adolescents with moderate to severe atopic dermatitis[1],[2]
– If approved, this will be the fourth indication for RINVOQ in the European Union[3]
– The European Commission decision is anticipated in the third quarter of 2021

NORTH CHICAGO, Ill., June 25, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of RINVOQ® (upadacitinib), an oral, selective and reversible JAK inhibitor, for the expanded use in adults (15 mg or 30 mg, once daily) and adolescents 12 years and older (15 mg, once daily) with moderate to severe atopic dermatitis who are candidates for systemic therapy. RINVOQ is being studied in several immune-mediated inflammatory diseases.4-10

The CHMP positive opinion was supported by data from the global Phase 3 program evaluating more than 2,500 patients with moderate to severe atopic dermatitis across three global pivotal studies: Measure Up 1, Measure Up 2 and AD Up.1,2 Across the three studies, both doses of RINVOQ met all primary and secondary endpoints, demonstrating rapid and significant improvement in skin clearance and reduction in itch compared to placebo at week 16 and other time points (p<0.001) in patients with moderate to severe atopic dermatitis.1,2 The most commonly reported adverse events in patients treated with RINVOQ were acne, nasopharyngitis and upper respiratory tract infections.1,2

“This milestone is an important step forward in our journey to improve care for people living with atopic dermatitis,” said Michael Severino, M.D., vice chairman and president, AbbVie. “Despite available treatments, many people with moderate to severe forms of this disease continue to experience a relentless and burdensome cycle of skin and itch symptoms. We are encouraged that the CHMP has recognized RINVOQ’s potential as an additional treatment option for these patients.”

The CHMP positive opinion is a scientific recommendation for marketing authorization to the European Commission, which authorizes marketing approval in the European Union. The Marketing Authorization will be valid in all member states of the European Union, as well as Iceland, Liechtenstein, Norway and Northern Ireland. If approved, this will be the fourth indication for RINVOQ, and RINVOQ will be the first JAK inhibitor in the European Union to treat moderate to severe atopic dermatitis in both adults and adolescents 12 years and older.3

Tags: < Innovation
ShareTweetShareSend

Related Industries

Healthcare

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

May 18, 2023
Healthcare

Medtronic AccuRhythm AI technology receives 2023 MedTech Breakthrough Award as Best New Monitoring Solution

May 17, 2023
Healthcare

Amgen Responds to Ftc Action RE: Proposed Acquisition Of Horizon Therapeutics

May 17, 2023
Healthcare

Cardinal Health Canada to open new distribution center in Ontario

May 11, 2023
Healthcare

Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets

May 10, 2023
Healthcare

Lilly’s Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation

May 10, 2023

Benjamin Michajlyszyn Joins Hyundai Motor North America as Director, Safety Test and Investigations Laboratory

May 18, 2023

...

Microsoft announces new AI solutions for Microsoft Cloud for Nonprofit: a game-changer for fundraising and volunteer engagement

May 16, 2023

...

IonicBlue® receives up to CAD $100 million investment from Canada Infrastructure Bank toward decarbonization projects

May 24, 2023

...

Rockwell Automation and Avid Solutions Partner to Accelerate and Scale Green Hydrogen Production

May 18, 2023

...

Otis is Again a DiversityInc Noteworthy Company

May 4, 2023

...

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

May 18, 2023

...

Hitachi Energy, the partner of choice for largest-ever HVDC wind energy project in U.S.

May 5, 2023

...

PPG Board of Directors recognized as ‘Public Company Board of the Year’

May 13, 2023

...

Baxter Announces CFO Transition

May 10, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NA-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NA-BIZ.COM All rights reserved.